Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199284 | 0.93 | MAPT (0.59) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL2199352 | 0.90 | MAPK13 (0.63) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL2198814 | 0.89 | MAPK14 (0.57) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL2203090 | 0.86 | MAPK13 (0.59) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL2200365 | 0.86 | MAPK14 (0.52) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL2197594 | 0.85 | MAPK13 (0.61) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL2196210 | 0.85 | MAPK13 (0.57) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL2200072 | 0.84 | MAPK13 (0.53) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL2199080 | 0.83 | MAPK14 (0.55) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 | |
| SCHEMBL2201091 | 0.83 | MAPK13 (0.55) | NPC1RAB9ASMN1; SMN2MAPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | claimed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | claimed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | claimed |
| JP-2006528597-A | — | — | 2006-12-21 | — | — | JP | claimed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | claimed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | claimed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | claimed |
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | NPC1 2170/4885RAB9A 1123/4885SMN1; SMN2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.